Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

Christine Birchwood,Jinglan Pei,Rebecca Finch,Graeme Jones,Margaret Michalska,Arthur Kavanaugh,Vibeke Strand,Cem Gabay,Katie Tuckwell

doi:10.1136/rmdopen-2017-000496

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

Christine Birchwood, Jinglan Pei + Show 7 more

Open Access

https://doi.org/10.1136/rmdopen-2017-000496

Copy DOI

Journal: RMD Open	Publication Date: Sep 1, 2017
Citations: 17	License type: open-access

Affiliation: Roche (United Kingdom), University of Tasmania, University of California, San Diego, Stanford University, University Hospital of Geneva

#Short Form-36 Mental Component Summary #Short Form-36 Physical Component Summary + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveTwo randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This...

Full Text